Novolog insulin aspart

Insurance formulary churn is the single biggest Novolog adherence threat: patients describe being cut off mid-supply without warning, forcing emergency workarounds and eroding brand loyalty regardless of clinical satisfaction.

• Insurance-driven formulary switches dominate the Novolog conversation, with patients describing week-long supply gaps and forced transitions to Humalog as a systemic access crisis rather than a clinical decision.
• FlexPen device complaints, specifically needle threading failures, perceived dose inaccuracy, and leakage, represent a distinct, hardware-level adherence risk that undermines confidence even when the molecule itself is trusted.
• Weight gain and fluid retention are the top reason Type 2 patients discontinue or express extreme dissatisfaction, with some reporting 60-pound gains that patients attribute directly to Novolog therapy.
• Generic and biosimilar alternatives (ReliOn NovoLog, Amazon Pharmacy generic) are organically discovered by cost-burdened patients, signaling strong pull toward lower-cost options that Novo Nordisk can either lead or lose to.